

5-Minute Journal Club: New Directions and Approaches in the Management of HER2-Altered Non-Small Cell Lung Cancer — Issue 2

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. What was the approximate objective response rate in cohort 2 of the Beamion LUNG-1 study which evaluated zongertinib for patients with previously treated advanced non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain (TKD) mutations?
 - a. 14%
 - b. 37%
 - c. 54%
 - d. 77%
 - e. 100%
2. What is the mechanism of action of zongertinib?
 - a. Tyrosine kinase inhibitor (TKI) targeting both HER2 and EGFR
 - b. HER2-specific, EGFR-sparing TKI
 - c. HER2-specific, KRAS-sparing TKI
3. Which of the following best describes the regulatory status of zongertinib?
 - a. Investigational, in clinical-stage development
 - b. FDA approved for patients with advanced NSCLC with HER2 TKD mutations after prior systemic therapy
 - c. FDA approved for patients with advanced NSCLC with HER2 overexpression (IHC 3+) after prior systemic therapy
 - d. FDA approved in combination with platinum-based chemotherapy for patients with previously untreated, advanced HER2-mutant NSCLC
4. Which of the following side effects is most associated with sevabertinib?
 - a. Neutropenia
 - b. Diarrhea
 - c. Anemia